1.1)State Key Laboratory of Brain and Cognitive Sciences, Institute of Biophysics, University of Chinese Academy of Sciences, Beijing 100101, China;2.2)Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
Fibronectin (FN) is an important molecule that participates in hepatitis B infection and fibrosis. Lumbrokinase (LK) is synthesized by earthworms containing a group of proteolytic isozymes, which were used to hydrolyze fibrin in the treatment of clotting disease. One of the isozymes purified from the LK compound was verified as a hydrolase to degrade FN in vitro and was called earthworm fibronectin hydrolase (EFNase). However, whether LK functions to prevent the deterioration of hepatitis B virus (HBV) infection has not been clarified. In this study, we used HepG2.2.15 cells to investigate the effect of LK on the level of hepatitis B surface antigen (HBsAg) or FN, used C57BL/6J-HBV transgenic mice to explore the effect on the level of HBsAg, FN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum, the pathological changes in livers. The results indicated that LK could inhibit HBsAg production in vitro and in vivo; decreased FN in serum and liver. Compared with physiological saline, LK improved the state of the livers. Those data provided valuable information to understand the therapeutic role of LK as a potentially effective medicine to treat chronic hepatitis B (CHB).
WANG Xue-Qing, WANG Xiu-Mei, HE Rong-Qiao. Lumbrokinase in a potential function to intervene chronic hepatitis B*[J]. Progress in Biochemistry and Biophysics,2020,47(8):780-789
Copy® 2024 All Rights Reserved ICP:京ICP备05023138号-1 京公网安备 11010502031771号